We have a new paper out, which shows that silencing a hypoxia-responsive gene can cause glioblastoma stem cells to revert to a less malignant phenotype: https://cdrjournal.com/article/view/3373. Great job Leora and Shaili!
I currently have a search ongoing for a postdoctoral associate to work on our NIH-funded project on nanomedicines that penetrate bacteria biofilms and cystic fibrosis mucus. Details and applications to https://jobs.rutgers.edu/postings/112387.
The NIH has awarded us a two-year R21 grant in the amount of $420,025 to support our project “Surface Active Polyelectrolyte Nanomedicine for Treatment of Lung Infections in Cystic Fibrosis.” This support will allow us to study and optimize the mucus and biofilm penetrating properties of our polyelectrolyte-based nanoparticles, which will ultimately enable improved delivery … Read More
Our project “GRAPLON Aerosolized Nanomedicines for Treating Cystic Fibrosis Lung Infections” has been selected as a finalist for a QED Proof-of-Concept award from the Science Center in Philadelphia. This program provides funding and business advice to help academic researchers commercialize promising technologies. News release at https://sciencecenter.org/news/finalists-named-in-the-science-center-s-qed-proof-of-concept-program-for-academic-researchers
Charlie was one of the recipients at Rutgers ORED’s Patent Award Reception for his allowed patent with Dave Devore, “Graft Copolymer Polyelectrolyte Complexes for Drug Delivery.”